We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Solo titulares de alta señal — eventos macro, earnings, M&A, regulación. Listicles y clickbait de analistas filtrados por defecto. Refrescado cada hora.
In the last week, the market has stayed flat, yet it is up 24% over the past year with earnings forecasted to grow by 17% annually. In such a vibrant market environment, identifying undervalued stocks can provide investors with opportunities to capitalize on potential growth at a discounted price.
Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In this context of robust market performance, identifying stocks that are trading below their fair value can be a strategic move for investors seeking opportunities for potential growth and value.
AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set them apart.
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.
Realty Income (NYSE:O) is dominating dividend feeds on Reddit and X again, with monthly-payer loyalists pointing to its 113th consecutive quarterly dividend increase as proof you can collect a check and tune out the rest of the market. The underlying numbers tell a different story. The Math On O Has Quietly Broken O trades at ... Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now
Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.
ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.
AbbVie Inc.'s ( NYSE:ABBV ) stock was strong despite it releasing a soft earnings report last week. Our analysis...
Over the last 7 days, the United States market has risen by 1.1%, contributing to a remarkable 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying stocks that may be undervalued can present opportunities for investors seeking potential value plays amidst strong market performance.
We recently published Jim Cramer Revealed His Big AI Investing Fear & Discussed These 20 Stocks. AbbVie Inc. (NYSE:ABBV) is one of the stocks discussed by Jim Cramer. Pharmaceutical firm AbbVie Inc. (NYSE:ABBV)’s shares are up by 11% over the past year and are down by 9% year-to-date. Evercore ISI was out with optimistic coverage […]
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
AI demand and pipeline growth headline top Zacks stock reports on NVIDIA, Mastercard and AbbVie.
AbbVie (ABBV) is back in focus after presenting fresh real world and long term data for its key immunology drugs SKYRIZI and RINVOQ at the 2026 Digestive Disease Week meeting. See our latest analysis for AbbVie. Those fresh immunology data and a string of recent conference appearances come as AbbVie’s share price has eased this year, with a year to date share price return of down 9.35%, even though the 1 year total shareholder return is 14.17% and the 5 year total shareholder return is...
AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for the long term. AbbVie Inc. (NYSE:ABBV) received a rating update from Evercore ISI on May 4, with the firm lifting the price target on the stock to $236 from $232 while maintaining an Outperform rating on the shares. The company also announced […]
NVIDIA, Mastercard and AbbVie headline Zacks' top stock reports, with AI growth, payment trends and drug launches in focus.
How does a rising 3.4% dividend and a growing portfolio of drugs sound?
JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) and JPMorgan Nasdaq Equity Premium Income ETF (NYSEARCA:JEPQ) pull from very different stock universes. JEPI leans on S&P 500 names with a covered call overlay. JEPQ runs the same income playbook on the Nasdaq-100. The latest fact sheets show why that distinction matters in 2026. Defensive Blue Chips Anchor ... Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
It's not the news that AbbVie needed, given the challenging year it is having.
AbbVie (NYSE:ABBV) presented new long term clinical and real world data for its gastroenterology portfolio at the 2026 Digestive Disease Week. The data highlighted SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, with reports of sustained patient benefits and strong real world performance. These findings relate to AbbVie's efforts to address unmet clinical needs and reinforce its position in inflammatory bowel disease treatments. AbbVie is a large biopharmaceutical company with...
AbbVie has lagged the broader market over the past year, although Wall Street analysts remain moderately optimistic about the company’s long-term growth prospects and pipeline strength.
This mortgage REIT generates income by originating and managing commercial real estate loans across the United States.
Blackstone Mortgage Trust originates senior commercial real estate loans globally, generating income primarily from interest and dividends.
AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its drug pipeline and business development. Rob Michael, AbbVie’s chairman and chief executive officer,
This article explains in straightforward terms whether AbbVie at around US$202 per share still offers value or whether most of the opportunity has already been priced in. The stock has recently been mixed, with a 4.1% decline over the last 7 days and a 1.8% decline over the last 30 days. It still shows returns of 12.8% over 1 year, 54.0% over 3 years, and 109.7% over 5 years. Recent coverage has focused on AbbVie's position as a large US pharmaceuticals and biotech company and on how...
IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.
AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for the next 15 years. On April 30, AbbVie, in partnership with adMare BioInnovations, named RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award. This national competition is designed to support Quebec’s life sciences sector by supporting early-stage companies that align with […]
Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’ shortlists. Both entered 2026 with fresh distributions and updated holdings. The two funds chase dividends through very different rule sets, and the gap between them is wider than the surface suggests. Quality Screen vs. Yield ... Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain
Q1 earnings show this Dividend King still looks built for the long term.
In recent weeks, AbbVie reported first-quarter 2026 revenue of US$15,002 million, while also securing new Canadian formulary listings and reimbursement progress for SKYRIZI in ulcerative colitis alongside fresh clinical and regulatory updates for SKYRIZI and RINVOQ across inflammatory and autoimmune diseases. Together with an ongoing dividend record and advances in areas such as immunology, gastroenterology and oncology partnerships, these developments highlight how AbbVie is leaning on its...